Aviragen Therapeutics

Research ServicesGeorgia, United States11-50 Employees

Aviragen Therapeutics is a research services company based in Alpharetta, Georgia, that focused on discovering and developing direct-acting antivirals to treat infections with limited therapeutic options. Its work targeted viral infections that affect a broad patient population, with clinical-stage compounds intended to prevent or treat rhinovirus, respiratory syncytial virus, and human papillomavirus-related conditions. The company positioned itself within the antiviral and vaccine development landscape, pursuing therapeutic and preventive approaches before being acquired by Vaxart in 2017. Following the acquisition, Aviragen’s activities and legacy projects are reflected in the broader trajectory of Vaxart’s oral vaccine development initiatives. Notable recent developments indicate ongoing work on gene-based vaccine platforms and preclinical testing, suggesting a continued focus on vaccine and antiviral strategies from its legacy programs. The organization operated in a research context with a small- to mid-sized footprint, reinforcing its role as a specialized partner in antiviral discovery and early development within the United States.

Sign up for free to view info

Email Format Employee directory